chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shingles; Abdomen started to bloat and becamne incredibly swollen; Sore arm; A spontaneous report was received from a consumer concerning a 61-year-old male who received Moderna's COVID-19 vaccine (mRNA-1273) and developed shingles/ Herpes zoster, abdominal started to bloat and became incredibly swollen/abdominal distension and sore arm/injection site pain.  The patient's medical history included hepatic cancer and unspecified liver procedure. Concomitant products known to have been used within two weeks prior to the vaccination included pembrolizumab.  On 19 Feb 2021, the patient received her first dose of mRNA-1273 (batch number: not provided) intramuscularly for prophylaxis of COVID-19 infection.   On 19FEB2021 the patient had a sore arm.  On 24 Feb 2021, the patient developed shingles which broke out all over his face affecting his lips, ears, gums and inside of his mouth. His abdomen started to bloat and became incredibly swollen. It was unknown if he received any treatment in response to the events.   Action taken with mRNA-1273 and pembrolizumab in the response to the events shingles, abdomen started to bloat and became incredibly swollen and sore arm was not known.  The outcome of the events, herpes zoster, abdominal distention and injection site pain were unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient developed a temperature of 104 degrees & had a febrile seizure requiring ER room visit approximately 8 hours after vaccine administration.
He was exploded to COVID-19 prior to being vaccinated but never tested positive. He was vomiting, congestion, and coughing. He was coughing for like 5 minutes straight, so I gave him a nebulizer treatment. The next day he started coughing so bad that he vomited 4 or 5 times, so I took him to the doctor. He was prescribed azithromycin and ZYRTEC. He had 5 days' worth of antibiotics and finished the ZYRTEC 2 days ago and has improved a lot.
patient was administered Flublok vaccine- it is indicated for 18+ years of age. patient was 13yrs old
ONE OF FOUR PTS WHO EXPER. EPISODE CONSISTING OF FAINTING AND/OR SHORTNESS OF BREATH, INCREASE IN PULSE RATE, DIAPHORESIS AND LIGHT-HEADNESS FOLLOWING IMMUNIZATION.
I broke out in a red rash on both arms 3 days after 1st shot & this shot I am reporting  red rash appeared on both arms within  4 hrs.  No treatment. It went away in about 5 or 6 days.
Brain fog; headache; nausea; RN administered 1 ml instead of 0.5ml of Moderna vaccine; This spontaneous case was reported by a nurse and describes the occurrence of FEELING ABNORMAL (Brain fog), HEADACHE (headache), NAUSEA (nausea) and ACCIDENTAL OVERDOSE (RN administered 1 ml instead of 0.5ml of Moderna vaccine) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 ml. On 06-Apr-2021, the patient experienced ACCIDENTAL OVERDOSE (RN administered 1 ml instead of 0.5ml of Moderna vaccine). On 07-Apr-2021, the patient experienced FEELING ABNORMAL (Brain fog), HEADACHE (headache) and NAUSEA (nausea). On 06-Apr-2021, ACCIDENTAL OVERDOSE (RN administered 1 ml instead of 0.5ml of Moderna vaccine) had resolved. At the time of the report, FEELING ABNORMAL (Brain fog), HEADACHE (headache) and NAUSEA (nausea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  The patient did not receive any treatment medications.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jun-2021: updated event outcome. On 22-Jul-2021: Follow-up contains no significant information.
swelling started about 8PM 16MAR98 (or noticed by mom) lt arm deltoid;also fussy;17MAR98 lt upper arm near inj site started to redden by 18MAR98 swelling had stayed the same in size but redness had tripled in size;
Patient complains of fevers tmax 102, chills, body aches, chest pains, nausea, vomiting. Relieved by tylenol.
Pt had no adverse event but was given a booster shot at the age of 15 instead of 16
During late August I experienced shortness of breath, extreme night sweats, cramps in legs, the start of varicose veins (noted first in June 2021 by my primary care) fatigue, day sweats and hot flashes, and general fatigue, wide ranging blood pressure
This case was reported by a nurse and described the occurrence of injection site pain in an unspecified number of patients who received FLUARIX QUADRIVALENT. On an unknown date, the patients received FLUARIX QUADRIVALENT, the patients experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site pain to be related to FLUARIX QUADRIVALENT. It was unknown if the reporter considered the injection site pain to be related to FLUARIX QUADRIVALENT. Additional details were provided as follows: The age at vaccination was not reported. The reporter stated she had administered over 500 shots of FLUARIX and experienced soreness at injection site. This case is one of the 4 cases, reported by the same reporter.
lightheadedness, ringing in ears. This happened after the first dose of COVID vaccine as well. VSS. Discharged in stable condition.
pt recv vax; T 101 on 13may95;MD called;pt sponged & given advil & apap;took to MD when pt devel rash & would not put weight on her knees; no tx given;
I developed shingles.   First sign May 1, first rash May 2, diagnosed May 6; This is a spontaneous report received from a contactable consumer.  A 45-year-old male consumer (patient) reported that received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number EW0151), into the left arm on 06Apr2021 09:15 (at the age of 45-years-old) at single dose for COVID-19 immunization. The patient had received first dose of vaccine on 9Mar2021 09:15 AM (lot Number: EN6206) in Arm Left.  Medical history was none.  The patient's concomitant medications were none.   The consumer reported that developed shingles. First sign on 01May2021, first rash on 02May2021, and was diagnosed on 06May2021. The event resulted in Doctor or other healthcare professional office/clinic visit. The patient received treatment with 'medicine'. Since the vaccination,  the patient has not been tested for COVID-19. The outcome of the event was recovering.   No follow-up attempts are needed. No further information is expected.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. There was no information about concomitant therapy, pertinent medical history, drug reactions and allergies provided. On 23-JUL-2015, the patient was subcutaneously vaccinated with an expired dose of VARIVAX 0.5ml injection (lot# J008980, expiration date 19-JUL-2015). No adverse experience was reported and no product quality complaints (PQC) were involved. Additional information has been requested.
Pain in left kidney area that did not intensify or diminish after onset. After two days pain traveled in a band around to the left abdomen region. Rash developed on abdomen on seventh day. Doctor visit. Prescribed anti-viral 5x/day for one week. After one week proscribed second type of anti-viral 3x/day for one week. By this date (11/20/2015) pain has subsided, rash is gone. Pain was never very intense (2 out of 10).
Case number PHEH2014US001201 is an initial spontaneous report from a nurse received on 14 Jan 2014. This report refers to a male child. The patient received FLUVIRIN (batch number: 1308401, expiry Mar 2014) intramuscularly on 09 Jan 2014. The nurse stated that patient was under the age of four and received FLUVIRIN. No further information was reported.
Pt reports fever and chills about 24 hours after receiving the PNEUMOVAX 23 vaccine. Temperature max was 102 degrees F. 48 hours later patient reports feeling much better no chills, temperature 100 degree F.
Patient received booster dose of monovalent vaccine 48 hours after it was announced to no longer administer monovalent vaccine as booster doses. Patient was unharmed and aware of the dose she was receiving at the time.
Pt received COVID Moderna vaccine on 2/11 at Family Clinic. Documented given IM in RIGHT deltoid. However, she says in LEFT arm.  After 20 minutes, no symptoms. About 5 hours later she had generalized weakness, especially noted when  getting out of her car. Son in clinic with her appreciated worsened weakness. At midnight woke up with body aches, tripped  in the bathroom, did not fall but leaned into wall. She  did not hit head or face. She looked in mirror and her left side of face was red, swollen, tender, firm to touch and noted herleft arm and bilateral LE weaker.  Denies paresthesias, changes in speech or cognition. After multiple clarifications with  interpreter, pt states just discomfort/aching and weakness. However, her physical exam was with decreased sensation along left Cranial nerve V2 and all of left arm. Significant left arm drop/drift. Right extremity slight generalized weakness, bilateral lower extremities slight generalized weakness- no paresthesias.
I had a respiratory illness moving between my nose and my chest. I thought I had RSV. I was very congested in my nose then it went into my chest. I had low energy and a low grade fever. I started feeling bad on May 5, 2022. I went to a wedding on May 7th and then the after party on May 8th. On May9th, 10th, and 11th I stayed home. My daughter tested positive for covid on May 8th and my wife tested positive for covid on May 9th. I felt better on May 9th and 10th, but on May 11th I started to feel worse with a mild fever. On May 12th I got a PCR test and me and my son both tested posive for covid that day. On May 13th I called Dr. and he prescribed paxlovid. I picked up the medication on May 14th.  The paxlovid helped tremendously. The fever went down, and after 2 days I felt better. I was able to do yard work and repairs around the house. I was off for 8 days from work.  My cough and congestion is a lot less now,  but I still have nose and chest congestion with phlegm.
Headache, muscle ache, fever, chills, nausea, fatigue, brain fuzz.    Treated by bedrest.  Took several days to go away.
Information has been received from a current 64 year old male patient with no drug reactions/allergies and no pertinent medical history, who in August 2011, was vaccinated with a dose of ZOSTAVAX (Merck) (dose, route and lot number not reported). Concomitant therapy included LIPITOR and unspecified "low dose blood pressure medication". The patient reported that approximately five days after receiving ZOSTAVAX (Merck) on an unspecified date in August 2011, when he was 63 year old, he was hospitalized for approximately five days. The patient reported that he felt dizzy, could not walk right, had coordination difficulties - he stated: "I reached for my doctor's hand and missed it by at least a foot" - and vision changes. There were multiple antibiotics and other medications given for the treatment for dizziness, inability to walk right, coordination difficulties and vision changes. The patient reported that everyone around him was convinced that he had a stroke, that multiple magnetic resonance imaging tests and other tests confirmed that no stroke had occurred. The patient reported that most of his symptoms have resolved. The patient stated that he still "lists to one side when walking". This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report as received from a certified medical assistant, refers to an unknown number of patients of unknown demographics. The patient's concurrent conditions and medical history were not reported. On an unknown date in 2013, an unspecified number of patients received improperly stored Vaccine For Children (VFC) doses of RECOMBIVAX HB (dose and route, lot and expiration date were not reported) exposed to 20F and 30F on multiple occasions, from 22-SEP-2013 until 20-DEC-2013 (for 122 days. No adverse effects were reported (the reporter stated that the vaccines administered were RECOMBIVAX HB and VAQTA) but on a second call was reported that no doses of VAQTA were involved in this excursion). Follow up information has been received from the certified medical assistant which reported that one of the patients was vaccinated with a dose of RECOMBIVAX HB (lot number reported as J0030722) on 26-AUG-2013. This is one of several reports from the same source. J0030722 is not valid lot number for RECOMBIVAX HB. Additional information has been requested.
herpes zoster; Information has been received regarding a case in litigation, from a lawyer, concerning a decedent patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  In 2016 the patient was vaccinated with zoster vaccine live(ZOSTAVAX), due to health care professional recommendation, for permanent prevention and protection against shingles and zoster-related injuries (prophylaxis) (strength, anatomical location, dose, route of administration, lot # and expiration date were not provided).  On an unknown date, the decedent was diagnosed with herpes zoster. On an unknown date the patient was treated for the event from the physician. At the time of report, the outcome of the event was unknown. The reporter considered the adverse events to be related to Zoster Vaccine Live(ZOSTAVAX).
vaccine expired on 01-Apr-2022 was stored in refrigerator on 04 Apr 2022 and administered on  19-Apr-2022; Expired vaccine administered to patient; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) and PRODUCT STORAGE ERROR (vaccine expired on 01-Apr-2022 was stored in refrigerator on 04 Apr 2022 and administered on  19-Apr-2022) in a 68-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 19-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vaccine expired on 01-Apr-2022 was stored in refrigerator on 04 Apr 2022 and administered on  19-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered to patient) and PRODUCT STORAGE ERROR (vaccine expired on 01-Apr-2022 was stored in refrigerator on 04 Apr 2022 and administered on  19-Apr-2022) outcome was unknown. Not Provided   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was stored in refrigerator on 04 Apr 2022.  The vial did not undergo temperature excursion.  No treatment medications were reported.   This case was linked to MOD-2022-551714 (Patient Link).
2-3hr p/vax tongue & throat were swelling, EMS called, pt intubated;pt c/o SOB, chest pain;no local reaction noted;
Possible self-innoculation to right collarbone.  Very limited, single pustule, with bordering erythema.
silght rash on chest; sore at the injection site; This case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In January 2022, the patient received the 1st dose of Shingrix. In January 2022, less than a week after receiving Shingrix, the patient experienced injection site pain and rash. On an unknown date, the outcome of the injection site pain and rash were Not Recovered/Not Resolved.   It was unknown if the reporter considered the injection site pain and rash to be related to Shingrix.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient received the first Shingrix dose about 46 hours prior to the reporting date.  No side effects except for a sore arm at the injection site, but on the reporting day, 46 hours later patient had a slight rash on chest.  The patient had temperature of 98.2 degree Fahrenheit. The follow-up would not possible as no contact details were available.
Moderna COVID-19 Vaccine EUA. Dose 2 Chills and Fever up to 102 orally starting about 6 hours after vaccine. Joint pain knees and neck, headache, lack of appetite, depression, rapid heart rate. Fever lasted about 2 days. Joint pain was severe the night after the vaccine but was gone by the morning. Headache lasted about a day and a half.  Felt weak but may be from no appetite.
Weird Voice; Vomited; Headache; Very Tired; Dizzy; Feels Sick; Runny nose; Joint pains; Body aches and pains; The chills; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Feels Sick), RHINORRHOEA (Runny nose), DIZZINESS (Dizzy), DYSPHONIA (Weird Voice) and ARTHRALGIA (Joint pains) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 012M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included PACLITAXEL (PAXEL), RIFABUTIN (RIBUTIN) and ATORVASTATIN for an unknown indication.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Feb-2021, the patient experienced ILLNESS (Feels Sick), RHINORRHOEA (Runny nose), ARTHRALGIA (Joint pains), MYALGIA (Body aches and pains) and CHILLS (The chills). On 23-Feb-2021, the patient experienced DIZZINESS (Dizzy). 23-Feb-2021, the patient experienced VOMITING (Vomited), HEADACHE (Headache) and FATIGUE (Very Tired). On 24-Feb-2021, the patient experienced DYSPHONIA (Weird Voice). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, ILLNESS (Feels Sick), RHINORRHOEA (Runny nose), DIZZINESS (Dizzy), DYSPHONIA (Weird Voice), ARTHRALGIA (Joint pains), MYALGIA (Body aches and pains), CHILLS (The chills), VOMITING (Vomited), HEADACHE (Headache) and FATIGUE (Very Tired) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Non-Significant Follow-up received on 14-July-2021 and contains updated reporter contact information
pt recvd vax; napped all am; would not stay awake; t of 104 R; to er; t 103; ibuprofen given; MD did not think Dpt was the problem; can have dtp again;
Severe Tinnitus in both ears; I never had tinnitus one day in my life until taking the vaccine. Since taking the vaccine, I have near constant tinnitus. It is very severe and often does not go away for several days. When it does seem to go away, it will typically return in about 24 hours. Rarely has a full day passed since it started where it was not present. I went to see a doctor. I told him I had never had tinnitus before taking the vaccine and he said there was absolutely no possibility of it being the cause. I told him I did not believe that and was certain it was an adverse reaction from the Covid vaccine. Since then, I have been researching and it appears I'm not the only person to have the adverse reaction. I have recently called his office and told them that I wanted it reported as an adverse reaction on my behalf. All they said was he made a note in my file about it but acted like it wouldn't be reported.
I started having SOB. It got worst on Jan 13th, I had serve SOB and I fainted. I passed out for about 1 minute. I went to the ER. They did EKG, normal results. They did CT scan because my oxygen levels was low, showed that I had massive pulmonary embolism. The admitted me into the hospital. I was hospitalized for 3 days. They did ultrasound on my both legs, negative for blood clots. They did blood work, normal results. They are not sure what was causing the embolism. I am now on blood thinners medicine.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No information on medical history, concurrent conditions or concomitant drugs was provided. It was reported that the patient was administered ZOSTAVAX, single dose, subcutaneously on 22-APR-2014 and, inadvertently, was administered second dose of ZOSTAVAX on 05-MAY-2014. Sites of administrations, lot numbers and expiration dates were not provided. No adverse effects were reported. Additional information has been requested.
Patient presented to the pharmacy on 10/1/2018 with swelling from the lower triceps head to her elbow. The area was warm but not painful. The area presented similar to an insect bite.
This spontaneous report was received from a registered nurse via medical assistant and refers to a 14-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 19-SEP-2017, the patient was vaccinated with improperly stored VARIVAX (lot # M039317; expiry date: 20-SEP-2018) and M-M-R II (lot # M034387; expiry date: 19-JUL-2018) for prophylaxis. The dose of VARIVAX was reconstituted with properly stored sterile diluent (MERCK). The doses of VARIVAX were exposed to temperature range between 6° Fahrenheit (F) to 14°F during a time frame of 1 hour 20 minutes. There were no previous temperature excursions. Digital data logger was involved. No adverse effects were reported. Product Quality Complaint (PQC) was not involved. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666 US-009507513-1710USA014650: Original Case: 1710USA014649 US-009507513-1710USA014651: Original Case: 1710USA014649.